International bowel cancer study led by UL and UHL researchers

The Rising Tide of Early-Onset Bowel Cancer: What the Future Holds

For decades, bowel cancer was largely viewed as a condition affecting older populations. Although, a concerning shift is occurring globally. Recent data indicates that one in ten cases of bowel cancer are now diagnosed in individuals under the age of 50.

This trend has sparked an urgent international effort to understand why younger generations are more susceptible to rectal and colorectal cancers than those born in previous decades. At the center of this effort is the Early Onset Colorectal Cancer (ECCE) study, a massive collaborative project coordinated by the World Health Organisation’s International Agency for Research on Cancer (IARC).

Unlocking the DNA ‘Fingerprint’ of Cancer

The future of cancer prevention lies in precision medicine. Researchers at the University of Limerick (UL) and the UL Hospital Group are leading Ireland’s contribution to the ECCE study by focusing on the genetic blueprints of the disease.

Professor Aedín Culhane, Director of the Limerick Digital Cancer Research Centre, is leading a team to analyze blood and tumor samples to identify specific DNA “fingerprints.” These fingerprints act as biological markers that can reveal the causes of genetic damage.

Tracing Environmental and Lifestyle Triggers

By reading these DNA patterns, scientists hope to determine if the rise in early-onset cases is linked to shared global exposures or specific local factors. Potential triggers being investigated include:

• Changes in modern diets.
• Environmental pollutants.
• Alterations in the gut microbiome.

As Professor Culhane notes, understanding these drivers is the first step toward developing better prevention strategies and improving outcomes for future generations.

The Screening Dilemma: Will the Age Limit Drop?

One of the most critical discussions in oncology today is the age at which screening should begin. In Ireland, bowel cancer screening is currently available for those aged 57 to 71. However, with the rise of cases in younger adults, this window may need to shift.

Professor Christina Fleming, a consultant colorectal surgeon in the UL Hospital Group, highlights a poignant reality: many young patients ask, “Why did this happen to me?” because they often lack the traditional risk factors associated with bowel cancer.

The goal of the ECCE study is to provide the scientific evidence necessary to support earlier screening. Because bowel cancer is highly treatable and curable when caught early, lowering the screening age could save countless lives by identifying the disease before it reaches an advanced stage.

Why Ireland is a Strategic Hub for Global Research

Interestingly, the rise of early-onset colorectal cancer appears to have happened later in Ireland compared to the UK and other European nations. Professor Paul Brennan of the World Health Organisation’s IARC describes this as a possible “time-lag.”

This lag provides a unique scientific opportunity. By studying the Irish population, researchers may be able to identify the exact moment and manner in which risk factors begin to influence cancer development. This insight could help predict future trends across other regions and allow for more preemptive medical interventions.

The Role of Patient Advocacy

Research is not just about data; it is about people. Patient advocates, such as Brendan Muldoon from Bowel Cancer Ireland, emphasize that colorectal cancer rates in people under 50 have nearly doubled in 25 years. This urgency is what drives the push for evidence-based policy changes and increased public awareness.

Frequently Asked Questions